New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
10:32 EDTGILD, IDIX, MRKGilead says Merck, Idenix acquistion 'makes sense'
Gilead (GILD) says it expects to see more advancement in the Hepititus C field. In terms of Merck's (MRK) recent acquisition of Idenix (IDIX), Gilead says the acquisition "makes sense" to them. Says this puts Gilead in a "strong position" and expects to see other company consolidations to catch up to where the company is. Says fully anticipates more competitors in the future with regiments and says the firm cannot predict who those future rivals will be at this time. Comments made at the Wells Fargo Healthcare conference.
News For GILD;MRK;IDIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 21, 2015
12:21 EDTGILDVertex rises after Bernstein suggests Gilead should pursue takeover
Subscribe for More Information
10:00 EDTGILDGilead spikes higher, levels to watch
Subscribe for More Information
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
08:30 EDTMRKMerck reaffirms commitment to developing medicines for infectious diseases
Merck reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases, including infections caused by resistant bacteria and other pathogens. At this year’s 25th European Congress of Clinical Microbiology and Infectious Diseases, April 25-28 in Copenhagen, Denmark, researchers are scheduled to present more than 30 scientific data presentations on the company’s broad portfolio of marketed and investigational anti-infective medicines. Merck completed its acquisition of Cubist Pharmaceuticals, Inc. on Jan. 21, 2015, and continues to build on both companies’ work in infectious disease. Antimicrobial research remains an important area of focus. In addition to a combined portfolio of antibiotic and antifungal medicines, vaccines, and medicines for HIV and HCV, Merck has multiple programs that span discovery through late-stage development. In total, Merck currently has more than 15 ongoing clinical trials evaluating antibiotic, antifungal and antiviral agents for the prevention and treatment of infectious disease. These trials are projected to enroll approximately 8,000 patients.
08:14 EDTGILDGilead should buy Vertex, says Bernstein
Subscribe for More Information
06:58 EDTGILDGilead May weekly volatility elevated into Q1 and outlook
Subscribe for More Information
April 20, 2015
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
08:05 EDTMRKTetraLogic, Merck enter into oncology clinical study collaboration
Subscribe for More Information
07:20 EDTGILD, MRKAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 19, 2015
19:35 EDTMRKMerck to swiftly repay $5B loan, explore acquisitions by late 2017, Reuters says
Subscribe for More Information
15:21 EDTMRKMerck announces new data from Keytruda study
Subscribe for More Information
14:59 EDTMRKMerck's Keytruda 'superior' to ipilimumab for PFS in patients with melanoma
Subscribe for More Information
14:47 EDTMRKMerck submits supplemental biologics license for Keytruda in lung cancer
Subscribe for More Information
14:31 EDTMRKMerck reports 28% Keytruda response rate in 25 pleural mesothelioma patients
Subscribe for More Information
April 15, 2015
16:01 EDTGILDOptions Update; April 15, 2015
iPath S&P 500 VIX Short-Term Futures down 49c to 21.90. Option volume leaders: AAPL NFLX C PBR KMI RIG MCP TWTR GILD BAC according to Track Data.
08:33 EDTMRKFDA panel results positive for Merck, says SunTrust
Subscribe for More Information
April 14, 2015
13:32 EDTMRKMerck, NewLink Genetics confirm initiation of Phase 3 trial of Ebola vaccine
Subscribe for More Information
April 13, 2015
16:01 EDTGILDOptions Update; April 13, 2015
Subscribe for More Information
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
08:58 EDTMRKMerck may have positive read through from briefing docs, says SunTrust
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use